Business of Biotechnology - Business ExchangeMost Active Articles2009-11-24T04:46:05.479-05:00Business ExchangeBusiness_Exchange@businessweek.comurn:com:businessweek:bx:topic:most-active:business-of-biotechnologyArlene Weintraubaweintraub678Singularity University Gives Execs a View of the Futureurn:com:businessweek:bx:article:10670926642387684372-7e5902d88ab30c01cb98d98fd72d45b62009-11-17T13:56:15.936-05:00In his various roles as a computer programmer, an emergency-medicine physician, and the director of Microsoft (MSFT) Medical Media Lab, Michael Gillam stays well ahead of the advances that are transforming health care. Yet even he can be caught...In his various roles as a computer programmer, an emergency-medicine physician, and the director of Microsoft (MSFT) Medical Media Lab, Michael Gillam stays well ahead of the advances that are transforming health care. Yet even he can be caught...BusinessWeek.com -- Technologyhttp://www.businessweek.com/technology/content/nov2009/tc20091116_310553.htmTom Gilestgiles6031001Cancer - Clinical trials Phase 1 trials, Research blog of Veeda Groupurn:com:businessweek:bx:article:6164801333215536596-1a345c6f0ea428e2cca4fbb80b51afd82009-11-10T07:15:33.091-05:00A "2" way approach to business The Cancer Health forecasts are very promising and are expected to grow at a rate which is higher than the world pharma market growth rate. The market is expected to reach a an approximate size of greater than US $ 75...A "2" way approach to business The Cancer Health forecasts are very promising and are expected to grow at a rate which is higher than the world pharma market growth rate. The market is expected to reach a an approximate size of greater than US $ 75...blogs.veedacr.comhttp://blogs.veedacr.com/Lists/Categories/Category.aspx?Name=CancerRashmi Pantrpant5371100Breast Cancer Vaccine Tests German Merck’s $1 Billion Strategyurn:com:businessweek:bx:article:9906666587082922265-00eaeb34eb167e31a0f61972b70514d02009-11-04T01:50:08.505-05:00Nov. 4 (Bloomberg) -- Merck KGaA of Germany is gambling an unproven therapy that spurs the immune system to attack cancer cells will increase its share of a $48 billion oncology market. Merck is enrolling more than 900 women globally in an...Nov. 4 (Bloomberg) -- Merck KGaA of Germany is gambling an unproven therapy that spurs the immune system to attack cancer cells will increase its share of a $48 billion oncology market. Merck is enrolling more than 900 women globally in an...bloomberg.comhttp://www.bloomberg.com/apps/news?pid=20601085&sid=aD2rO8iba81URashmi Pantrpant5372200Takeda to Pay Amylin Up to $1 Billion to Develop Obesity Drugsurn:com:businessweek:bx:article:17692315651120320024-c827f812ad576ac240ecba365f0f8a9e2009-11-01T23:57:28.700-05:00Nov. 2 (Bloomberg) -- Takeda Pharmaceutical Co., maker of the world’s best-selling diabetes drug, agreed to pay as much as $1 billion, including $75 million upfront, to Amylin Pharmaceuticals Inc. to co-develop obesity treatments. The deal includes...Nov. 2 (Bloomberg) -- Takeda Pharmaceutical Co., maker of the world’s best-selling diabetes drug, agreed to pay as much as $1 billion, including $75 million upfront, to Amylin Pharmaceuticals Inc. to co-develop obesity treatments. The deal includes...bloomberg.comhttp://www.bloomberg.com/apps/news?pid=20601101&sid=apXSu7fDFI6wRashmi Pantrpant5370000Biotechnology Value Fund joins activist battle against Facet Biotechurn:com:businessweek:bx:article:4273720167249487436-43435c0dee2353be985058673cba6a852009-10-18T00:14:28.016-04:00From this week's Hedge Fund Solutions Catalyst Equity Research Report, we are highlighting the Biotechnology Value Fund's investment in immunology and oncology research and drug manufacturer Facet Biotech Corporation (NASDAQ: FACT).From this week's Hedge Fund Solutions Catalyst Equity Research Report, we are highlighting the Biotechnology Value Fund's investment in immunology and oncology research and drug manufacturer Facet Biotech Corporation (NASDAQ: FACT).hedgetracker.comhttp://www.hedgetracker.com/article/Biotechnology-Value-Fund-joins-activist-battle-against-Facet-BiotechTodd Walkerrwienke0850000Genomic Researcher Wins ‘The Economist’ Magazine’s Innovation Awardurn:com:businessweek:bx:article:4166367090664482889-329e46e06b0f1357a6efc6e897584ab32009-10-13T16:32:36.962-04:00New York, NY (AHN) – Genomic researcher J. Craig Venter has been awarded The Economist magazine’s Innovation Award for Bioscience for work with the “potential to revolutionize personal medicine, pharmaceuticals, and biofuels.”New York, NY (AHN) – Genomic researcher J. Craig Venter has been awarded The Economist magazine’s Innovation Award for Bioscience for work with the “potential to revolutionize personal medicine, pharmaceuticals, and biofuels.”inquisitr.comhttp://www.inquisitr.com/42187/genomic-researcher-wins-the-economist-magazines-innovation-award/Michael Arndtmarndt5611100Pfizer Suspends Lung Cancer Studyurn:com:businessweek:bx:article:9260794491300486463-bc461589c89f2c306f57cb73c51c87282009-10-09T15:49:45.964-04:00The drug giant suffers a setback in its effort to boost its oncology pipeline.The drug giant suffers a setback in its effort to boost its oncology pipeline.Forbes.comhttp://www.forbes.com/2009/10/09/cancer-figitumumab-pfizer-business-healthcare-cancer.html?partner=yahootixArlene Weintraubaweintraub6782200Talecris Biotherapeutics HOT Biotechnology Stockurn:com:businessweek:bx:article:3568875961712539169-bc264952cc39c8c8cd05fe51e7eecb6b2009-09-30T12:00:22.417-04:00Talecris Biotherapeutics (TLCR) plans to go public this week. The biotech company is a maker of plasma-derived protein therapies, formerly for Bayer. According to FierceBiotech, the company had originally planned to go public back in 2007, before the market meltdown pushed share prices down. But Talecris, based in Research Triangle Park, put that plan aside when it inked a deal to merge with an Australian company. The merger deal, however, fell through after regulators raised antitrust concerns.Talecris Biotherapeutics (TLCR) plans to go public this week. The biotech company is a maker of plasma-derived protein therapies, formerly for Bayer. According to FierceBiotech, the company had originally planned to go public back in 2007, before the market meltdown pushed share prices down. But Talecris, based in Research Triangle Park, put that plan aside when it inked a deal to merge with an Australian company. The merger deal, however, fell through after regulators raised antitrust concerns.talecrisbiotherapeutics.blogspot.comhttp://talecrisbiotherapeutics.blogspot.com/James Rickmanjrickman0473300Clinical Remissions in Three Otherwise Intractable Cancers Signal the Progress of Targeted Genetic Medicine - Drugs and Pharmaceuticals Newsurn:com:businessweek:bx:article:1886215277412056934-f9df3a1906ef861b85474e122f90be8a2009-10-12T14:13:23.663-04:00Tumor-targeted REXIN-G Quells Metastatic Osteosarcoma, Prostate Cancer, and Pancreas Cancer as Stand-alone Therapy. SAN MARINO, Calif., Oct. 12 (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies Corporation today announced more stunning results of its...Tumor-targeted REXIN-G Quells Metastatic Osteosarcoma, Prostate Cancer, and Pancreas Cancer as Stand-alone Therapy. SAN MARINO, Calif., Oct. 12 (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies Corporation today announced more stunning results of its...send2press.comhttp://send2press.com/newswire/2009-10-1012-002.shtmlChristopher Simmonscsimmons2810000J&J Drug for Psoriasis Approvedurn:com:businessweek:bx:article:3154019985630703242-d8b0cd2299c0498bb9f1d8acc58064cc2009-09-25T14:48:46.996-04:00A new way of attacking the painful skin disease had received the green light from the FDA.A new way of attacking the painful skin disease had received the green light from the FDA.fda.govhttp://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm183851.htmArlene Weintraubaweintraub6784400The Hidden Costs Of Running A Biotech Company - Venture Capital Dispatchurn:com:businessweek:bx:article:471193138474372456-4d82138c9e6cac54a4a1c955c93257992009-09-22T09:43:53.311-04:00When VCs consider a biotech investment, they usually factor the direct costs of the studies they’re being asked to fund – what the company will spend per patient on things like enrollment and clinical-trial investigators. Many companies appear lean...When VCs consider a biotech investment, they usually factor the direct costs of the studies they’re being asked to fund – what the company will spend per patient on things like enrollment and clinical-trial investigators. Many companies appear lean...blogs.wsj.comhttp://blogs.wsj.com/venturecapital/2009/09/21/the-hidden-costs-of-running-a-biotech-companyTerri Griffithtgriffith9861100Investing in the Biotech Sector: 5 Elements To Consider urn:com:businessweek:bx:article:1610502861656954835-bddbf6bea85a13073ca595b384d459a82009-04-03T12:30:43.139-04:00When Arena Pharmaceuticals (Nasdaq: ARNA) released positive Phase III data on its obesity drug, Lorcaserin, many people expected shares...When Arena Pharmaceuticals (Nasdaq: ARNA) released positive Phase III data on its obesity drug, Lorcaserin, many people expected shares...contrarianprofits.comhttp://www.contrarianprofits.com/articles/investing-in-the-biotech-sector-5-elements-to-consider/15403Contrarian Profitscprofits175212100Merged Roche-Genentech shakes top mgmturn:com:businessweek:bx:article:6241403558788096511-c02368afb47472e4aeeb0bc177810fb72009-09-08T14:09:32.809-04:00Pascal Soriot, the man charged with integrating Roche Holding AG (SWX:ROG) and Genentech Inc. -- alongside former Genetech chief Arthur Levinson -- has a new post. And so do quite a few others at Roche, which rebranded itself as a biotech company after the acquisition.Pascal Soriot, the man charged with integrating Roche Holding AG (SWX:ROG) and Genentech Inc. -- alongside former Genetech chief Arthur Levinson -- has a new post. And so do quite a few others at Roche, which rebranded itself as a biotech company after the acquisition.thedeal.comhttp://www.thedeal.com/corporatedealmaker/2009/09/merged_roche-genentech_shakes.phpBrennen Wysongbwysong5982200Analyst Picks and Pans: Amgen, Coinstar, American Woodmarkurn:com:businessweek:bx:article:4808016451770405500-ee7975be3dabdfb476d3214c77762ccf2009-08-26T13:05:02.831-04:00Wall Street pored over new trial results for Amgen's anemia drug Aranesp on Aug. 26Wall Street pored over new trial results for Amgen's anemia drug Aranesp on Aug. 26BusinessWeekhttp://www.businessweek.com/investor/content/aug2009/pi20090826_829007.htmWilliam Andrewswandrews6432101Which Country Ranks Highest In Biotech Innovation?urn:com:businessweek:bx:article:13862472459570780006-ef459957fb899037cf5abb846688c0f42009-05-22T11:15:36.159-04:00A recent report issued by Scientific American, "Scientific American Worldview: A Global Biotechnology Perspective"ranked the countries with the highest level of biotech innovation. Medical News Today reports that "overall, the US had the highest final score, it did not come out on top for all five benchmarks: intellectual property, enterprise support, the intensity of a country's biotech activities, education/workforce, and infrastructure." The report continues, "although the US came out on top in intellectual property protections, Belgium, Canada, Denmark, France, Ireland, Italy, Japan, the Netherlands, and the UK weren't too far behind. The small country of Denmark, however, leads the world in the number of biotech patents per member of the population."
A recent report issued by Scientific American, "Scientific American Worldview: A Global Biotechnology Perspective"ranked the countries with the highest level of biotech innovation. Medical News Today reports that "overall, the US had the highest final score, it did not come out on top for all five benchmarks: intellectual property, enterprise support, the intensity of a country's biotech activities, education/workforce, and infrastructure." The report continues, "although the US came out on top in intellectual property protections, Belgium, Canada, Denmark, France, Ireland, Italy, Japan, the Netherlands, and the UK weren't too far behind. The small country of Denmark, however, leads the world in the number of biotech patents per member of the population."
frontendofinnovation.blogspot.comhttp://frontendofinnovation.blogspot.com/2009/05/which-country-ranks-highest-in-biotech.htmlMelissa Sundarammsundaram394141400Drugmakers May Fund Ad Campaign on Health Overhaulurn:com:businessweek:bx:article:5450386469868715725-09841259427169b4fde91939446475502009-07-30T10:35:17.270-04:00Drugmakers may push for an overhaul of the U.S. health care system by spending $100 million on ads starting as early as September.Drugmakers may push for an overhaul of the U.S. health care system by spending $100 million on ads starting as early as September.bloomberg.comhttp://www.bloomberg.com/apps/news?pid=20601109&sid=aHMaDF4PRvMQArlene Weintraubaweintraub6782011The Biotech Industry Finally Turns a Profit urn:com:businessweek:bx:article:9748590106719294353-ca0f1c9d752c0a7d527072043429cc792009-02-27T11:45:35.437-05:00They say that nobody should start a company to make money. Here’s proof: for all the buzz about biotech, in 40 years (really, 42, since Genentech’s founding in 1976), the biotech industry as a whole never made a profit — until last year.They say that nobody should start a company to make money. Here’s proof: for all the buzz about biotech, in 40 years (really, 42, since Genentech’s founding in 1976), the biotech industry as a whole never made a profit — until last year.industry.bnet.comhttp://industry.bnet.com/pharma/10001136/the-biotech-industry-finally-turns-a-profit/Cathy Arnstcarnst812212100Pfizer and Private Team Access Launch New Patient Recruitment Websiteurn:com:businessweek:bx:article:15700650110646574730-7423b953bce15eef704f7c320485780f2009-09-03T08:56:43.410-04:00According to this article in outsourcing-pharma.com Pfizer has teamed up with Private Access Team to boost trial recruitment over the web.According to this article in outsourcing-pharma.com Pfizer has teamed up with Private Access Team to boost trial recruitment over the web.partnershipswithcros.blogspot.comhttp://partnershipswithcros.blogspot.com/2009/08/pfizer-and-private-team-access-launch.htmlYemil Martinezymartinez8493300Democrats Go to Bat for Big Pharma urn:com:businessweek:bx:article:4112160684897712866-bd8c0325cd2dd04fb0e78c8a382fa3e42009-07-31T15:47:29.998-04:00Should a branded biotech get 5 years or 12 years of protection from generic competition?Should a branded biotech get 5 years or 12 years of protection from generic competition?thenation.comhttp://www.thenation.com/blogs/jstreet/457445/democrats_go_to_bat_for_big_pharmaArlene Weintraubaweintraub6782002Human Genome shares jump on Glaxo takeover chatterurn:com:businessweek:bx:article:7722278464162905289-6e9028a4ac98543a7358905b6f2c56d02009-08-25T16:04:31.829-04:00Human Genome Sciences Inc shares rose nearly 12 percent on Tuesday on rumors that Glaxo may buy the long-struggling biotech.Human Genome Sciences Inc shares rose nearly 12 percent on Tuesday on rumors that Glaxo may buy the long-struggling biotech.Reutershttp://www.reuters.com/article/marketsNews/idINN2522686720090825?rpc=44Arlene Weintraubaweintraub6780000Career Opportunities in Biotechnology and Drug Developmenturn:com:businessweek:bx:article:3033216558406058600-eccf9d1309b3fcb8ecc33a23560ed7e22009-07-30T13:02:43.359-04:00nonclinicaljobs.comhttp://www.nonclinicaljobs.com/2009/07/career-opportunities-in-biotechnology.htmlJoseph Kim, MD, MPHjkimmdmph2002200 Biotech Stocks Swing with Swine Flu-NVAX, BCRX, PURE Surge urn:com:businessweek:bx:article:12008981906224623753-0b4901eb2ae1bda53a54687ab94f4ec42009-04-27T12:02:32.328-04:00www.BiotechIndustryStocks.com, a global investor website for the biotechnology sector within Investorideas.com, presents a biotech stocks sector close- up on stocks moving on swine flu news and fears of a global pandemic. Companies providing potential solutions moved up as the market opened.www.BiotechIndustryStocks.com, a global investor website for the biotechnology sector within Investorideas.com, presents a biotech stocks sector close- up on stocks moving on swine flu news and fears of a global pandemic. Companies providing potential solutions moved up as the market opened.investorideas.comhttp://www.investorideas.com/News/042709e.aspDawn Van Zantdvanzant2297610Stem Cell Breaktrough urn:com:businessweek:bx:article:7654896235325595975-83e4ceb756fa2be7d49eb957a53d51be2009-05-27T16:47:19.216-04:00I have remarkable news for you. It ranks, in fact, among the great humanitarian breakthroughs of our age.
BioTime, Inc. (BTIM: OTCBB) CEO Dr. Michael West was the final speaker at the World Stem Cells & Regenerative Medicine Congress 2009. On May 14, he presented preliminary scientific data about his ability to program stem cells to become precursors to joint, cartilage and other skeletal cells. An in-depth peer-reviewed journal article will follow.I have remarkable news for you. It ranks, in fact, among the great humanitarian breakthroughs of our age.
BioTime, Inc. (BTIM: OTCBB) CEO Dr. Michael West was the final speaker at the World Stem Cells & Regenerative Medicine Congress 2009. On May 14, he presented preliminary scientific data about his ability to program stem cells to become precursors to joint, cartilage and other skeletal cells. An in-depth peer-reviewed journal article will follow.whiskeyandgunpowder.comhttp://whiskeyandgunpowder.com/stem-cell-breaktrough/Whiskey and Gunpowderwgunpowder3445500Bone Drug Key to Amgen's Futureurn:com:businessweek:bx:article:7777725177706872318-a451683e37434a5572af79bf0738ab842009-07-30T11:21:10.486-04:00Investors are eager for news on denosumab, which the FDA will be discussing soon.Investors are eager for news on denosumab, which the FDA will be discussing soon.fool.comhttp://www.fool.com/investing/high-growth/2009/07/28/amgen-secures-its-future.aspxArlene Weintraubaweintraub6781100The Future of Pharmaurn:com:businessweek:bx:article:3673726759187364238-e9ae30ef2367345827bd6373fd32e6492008-12-22T17:12:20.466-05:00Over the next few years, drug makers are likely to face many new challenges, including government approved importation of cheaper drugs, Medicare negotiating for lower prices, stricter regulations of direct-to-consumer advertising, and (hopefully) a more robust FDA under the Obama Administration. With so many changes afoot, Big Pharma will have to evolve or suffer the consequencesOver the next few years, drug makers are likely to face many new challenges, including government approved importation of cheaper drugs, Medicare negotiating for lower prices, stricter regulations of direct-to-consumer advertising, and (hopefully) a more robust FDA under the Obama Administration. With so many changes afoot, Big Pharma will have to evolve or suffer the consequencesHealth Beathttp://www.healthbeatblog.org/2008/12/the-future-of-pharma.htmlCathy Arnstcarnst812171610